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Hüter and colleagues recently published an experimental
paper about possible pathomechanisms of hydroxyethyl-
starch (HES)-induced adverse effects on renal function in an
isolated perfusion model of 6 hours [1]. The authors should
be congratulated for their attempt to shed light on the
influence of different HES preparations on renal function,
combining functional results and histological data.
In the recently published prospective, randomized, controlled
Efficacy of Volume Substitution and Insulin Therapy in Severe
Sepsis (VISEP) trial, 10% HES 200/05 caused a close to
significant increase in 90-day mortality in septic patients.
Renal failure and renal replacement therapy significantly
increased dose dependently compared with Ringer’s lactate
treatment. Unfortunately, 100 out of 262 patients in the HES
group received more than the maximum allowed daily dose on
at least 1 day, the majority occurring on the first day after
study inclusion. The patients without a violation of the
maximum daily dose administration had a mortality rate even
lower than that in the Ringer’s lactate group [2].
In their isolated renal perfusion model, Hüter and colleagues
tried to answer some of the questions originating from the
VISEP trial, comparing 10% HES 200/0.5, 6% HES 130/0.42
and Ringer’s lactate [1]. The hyperoncotic 10% HES, used in
the VISEP study, showed severe oliguria, impaired potassium
excretion and signs of lysosomal tubular damage. In contrast,
isovolemic 6% HES showed no difference compared with
Ringer’s lactate in creatinine clearance, sodium excretion and
N-acetyl-β-D-glucosamidase in urine. The 6% HES even
showed a decreased inflammatory reaction compared with
10% HES and Ringer’s lactate.
Interestingly, osmotic-nephrosis-like lesions were found in all
three groups, also to a lesser extent in the Ringer’s lactate
group. These lesions represent a quantity-dependent accumu-
lation of proximal tubular lysosomes due to administration of
exogenous solutes [3]. Principally, the lysosomal swelling is
reversible, but any process such as ischaemia or pre-existing
kidney damage that impairs lysosomal digestion further delays
degradation. The presence of osmotic nephrosis does not
necessarily have an impact on proximal tubular function [3].
The second significant difference between 6% HES and
Ringer’s lactate was the amount of urine produced [1]. The
authors take this together with the increased amount of
osmotic nephrosis as a sign of impaired renal function due to
6% HES. An alternative explanation for the difference in
urinary output would be 0.9% NaCl, the carrier fluid of the
HES solution. In an elegant animal model, Wilcox showed
that hyperosmolar chloride-containing solutes reduce renal
blood flow, the glomerular filtration rate, urinary output and
sodium reabsorption [4]. The depression of renal function
was even increased in hypovolemic, potassium-depleted
animals. Healthy young human volunteers showed a lower
urinary output, a longer time to first micturition and decreased
urinary sodium after infusion of 2 l of 0.9% NaCl compared
with Hartman’s solution [5].
In my opinion, the study by Hüter and colleagues experi-
mentally confirms the data from the VISEP study showing that
hyperoncotic 10% HES is nephrotoxic. They should not
extend their statement to isooncotic 6% HES because in
their study they only found small differences from Ringer’s
lactate – differences with debatable clinical relevance or
differences ascribable to saline.
Letter
10% Hydroxyethylstarch impairs renal function and induces
interstitial proliferation, macrophage infiltration and tubular
damage
Martin Siegemund
Department of Anaesthesia and Intensive Care Medicine, Surgical ICU, University Hospital Basel, Surgical ICU, Spitalstrasse 21, CH-4031 Basel,
Switzerland
Corresponding author: Martin Siegemund, siegemundm@uhbs.ch
Published: 8 July 2009 Critical Care 2009, 13:413 (doi:10.1186/cc7928)
This article is online at http://ccforum.com/content/13/4/413
© 2009 BioMed Central Ltd
See related research by Hüter et al., http://ccforum.com/content/13/1/R23
HES = hydroxyethylstarch; VISEP = Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis.Critical Care    Vol 13 No 4 Siegemund
Page 2 of 2
(page number not for citation purposes)
Author’s response
Lars Hüter, Tim-Philipp Simon, Lenard Weinmann, Tobias Schürholz, Konrad Reinhart, Gunter Wolf, 
Kerstin Ute Amann and Gernot Marx
Siegemund pointed out in his letter that according to our
study results 10% HES is nephrotoxic while 6% HES 130/0.42
is comparable with Ringer’s lactate in its effects. Siegemund
also suggested in his letter that this can be explained by the
hyperviscosity of 10% HES 200/0.5 and the solvent natural
saline [1].
We agree that a hyperviscous solution may by itself
aggravate renal impairment. This adds further arguments
against the use of 10% HES solutions. We used 10% HES
200/0.5 solution in a dosage that corresponds to 100% of
the maximal daily dosage and used 6% HES 130/0.42
solution in a dosage corresponding to 66% of the maximal
daily dosage in humans. These dosages resulted in a
comparable amount of 2 g/kg of both HES solutions. We
therefore agree with Siegemund’s comments that in our study
we found differences between 10% HES 200/0.5 and 6%
HES 130/0.42.
The concept of balanced solutions is currently widely
discussed. In experimental septic shock a balanced HES
preparation resulted in significant improved short-term
survival as compared with a saline-based resuscitation [6]. In
our study, however, both starches were solved in saline. The
suggested nephrotoxicity of saline in our model therefore
needs to be investigated in another study.
In our view, Siegemund drew a false conclusion from the
VISEP study results – claiming that ‘The patients without a
violation of the maximum daily dose administration had a
mortality rate even lower than that in the Ringer’s lactate
group’. This is an incorrect comparison, because it is not
possible to compare the mortality rate of one post-hoc
subgroup with the mortality rate of the overall crystalloid
group. The VISEP study showed that patients receiving 10%
HES 200/0.5 had no improved outcome over patients
receiving Ringer’s lactate at 28 days. Moreover, subgroup
analysis found that patients who had received a lower dose of
10% HES 200/0.5 also were more likely to have renal failure
than those who had received Ringer’s lactate (30.9% vs.
21.7%,  P = 0.04) and were more likely to need renal
replacement therapy (25.9% vs. 17.3%, P = 0.03) [2].
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